Multiple Myeloma

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

In this video, Sham Mailankody, MBBS discusses the biggest unmet needs in multiple myeloma treatment.

In this video, Sham Mailankody, MBBS discusses the biggest risk factors for multiple myeloma.

In this video, Sham Mailankody, MBBS discusses the latest in the study and treatment of multiple myeloma.

February is Black History Month.

SAN DIEGO — Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood cancers, according to retrospective data presented at ASH Annual Meeting and Exposition. Patients with commercial insurance and Medicaid had prescriptions rejected more often than patients with Medicare.

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.

The combination of talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.

SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.

Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.